{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T01:19:00Z","timestamp":1784942340403,"version":"3.55.0"},"reference-count":83,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.critrevonc.2025.104787","type":"journal-article","created":{"date-parts":[[2025,6,2]],"date-time":"2025-06-02T11:10:17Z","timestamp":1748862617000},"page":"104787","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Adverse effect of trastuzumab deruxtecan in solid tumours: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"213","author":[{"given":"Neha","family":"Pathak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Di Iorio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego Malon","family":"Gimenez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yael","family":"Berner-Wygoda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline","family":"Savill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amal","family":"Aljuhani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhenil","family":"Mittal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vikaash","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eitan","family":"Amir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.critrevonc.2025.104787_bib1","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1007\/s40265-022-01736-w","article-title":"Trastuzumab deruxtecan-induced interstitial lung disease\/pneumonitis in ERBB2-positive advanced solid malignancies: a systematic review","volume":"82","author":"Abuhelwa","year":"2022","journal-title":"Drugs"},{"key":"10.1016\/j.critrevonc.2025.104787_bib2","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.16_suppl.1009","article-title":"DESTINY-Breast07: dose-expansion interim analysis of T-DXd monotherapy and T-DXd +\u2009pertuzumab in patients with previously untreated HER2+\u2009mBC","volume":"42","author":"Andre","year":"2024","journal-title":"JCO"},{"key":"10.1016\/j.critrevonc.2025.104787_bib3","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1016\/S0140-6736(23)00725-0","article-title":"Trastuzumab deruxtecan versus treatment of physician\u2019s choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial","volume":"401","author":"Andr\u00e9","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.critrevonc.2025.104787_bib4","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1056\/NEJMoa2407086","article-title":"Trastuzumab deruxtecan after endocrine therapy in metastatic breast cancer","volume":"391","author":"Bardia","year":"2024","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.critrevonc.2025.104787_bib5","doi-asserted-by":"crossref","first-page":"GS2-03","DOI":"10.1158\/1538-7445.SABCS22-GS2-03","article-title":"Abstract GS2-03: GS2-03 TRIO-US B-12 TALENT: Neoadjuvant trastuzumab deruxtecan with or without anastrozole for HER2-low, HR+\u2009early stage breast cancer","volume":"83","author":"Bardia","year":"2023","journal-title":"Cancer Res."},{"key":"10.1016\/j.critrevonc.2025.104787_bib6","doi-asserted-by":"crossref","unstructured":"Bardia A., Hurvitz S., Press M.F., Wang L.S., McAndrew N.P., Chan D., Phan V., Villa D., Tetef M.L., Chamberlain E., Abdulla N., Lomis T., Spring L.M., Applebaum S., Dakhil S., DiCarlo B., Kim D.D., Kirimis E., Lawler W.E., Master A.K., McCann K., Hayashi E., Kivork C., Chauv J., 2023a. TRIO-US B-12 TALENT: Neoadjuvant trastuzumab deruxtecan with or without anastrozole for HER2-low, HR+\u2009early stage breast cancer. Cancer Res., 2022 San Antonio Breast Cancer Symposium. San Antonio, TX United States. 83. \u3008https:\/\/doi.org\/10.1158\/1538-7445.SABCS22-GS2-03\u3009.","DOI":"10.1158\/1538-7445.SABCS22-GS2-03"},{"key":"10.1016\/j.critrevonc.2025.104787_bib7","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1038\/s41591-022-01935-8","article-title":"Trastuzumab deruxtecan in HER2-positive breast cancer with brain metastases: a single-arm, phase 2 trial","volume":"28","author":"Bartsch","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.critrevonc.2025.104787_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2023.101425","article-title":"237P Real-world safety and efficacy of trastuzumab-deruxtecan (T-DXd) in HER2-positive advanced breast cancer (ABC) elderly patients (pts): The TREX-Old retrospective registry","volume":"8","author":"Buono","year":"2023","journal-title":"ESMO Open"},{"key":"10.1016\/j.critrevonc.2025.104787_bib9","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1016\/0895-4356(90)90093-5","article-title":"Indexes and boundaries for \u201cquantitative significance\u201d in statistical decisions","volume":"43","author":"Burnand","year":"1990","journal-title":"J. Clin. Epidemiol."},{"key":"10.1016\/j.critrevonc.2025.104787_bib10","doi-asserted-by":"crossref","first-page":"CT248","DOI":"10.1158\/1538-7445.AM2024-CT248","article-title":"Abstract CT248: Trastuzumab deruxtecan (T-DXd) in Chinese patients (pts) with previously treated HER2 mutant non-small cell lung cancer (NSCLC): primary analysis from the Phase\u00a02 DESTINY-Lung05 (DL-05) trial","volume":"84","author":"Cheng","year":"2024","journal-title":"Cancer Res."},{"key":"10.1016\/j.critrevonc.2025.104787_bib11","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1007\/s40264-023-01328-x","article-title":"Clinical guidance on the monitoring and management of trastuzumab deruxtecan (T-DXd)-related adverse events: insights from an Asia-Pacific multidisciplinary panel","volume":"46","author":"Chiu","year":"2023","journal-title":"Drug Saf."},{"key":"10.1016\/j.critrevonc.2025.104787_bib12","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/S1470-2045(23)00215-2","volume":"24","author":"Cutsem","year":"2023","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2025.104787_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.102113","article-title":"Toxicity profile of antibody-drug conjugates in breast cancer: practical considerations","volume":"62","author":"D\u2019Arienzo","year":"2023","journal-title":"eClinicalMedicine"},{"key":"10.1016\/j.critrevonc.2025.104787_bib14","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.clbc.2023.09.005","article-title":"Efficacy and safety of trastuzumab deruxtecan in breast cancer: a systematic review and meta-analysis","volume":"23","author":"Dowling","year":"2023","journal-title":"Clin. Breast Cancer"},{"key":"10.1016\/j.critrevonc.2025.104787_bib15","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/s12885-024-11851-4","article-title":"Neoadjuvant trastuzumab deruxtecan (T-DXd) with response-directed definitive therapy in early stage HER2-positive breast cancer: a phase II study protocol (SHAMROCK study)","volume":"24","author":"Dowling","year":"2024","journal-title":"BMC Cancer"},{"key":"10.1016\/j.critrevonc.2025.104787_bib16","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/s41571-021-00470-8","article-title":"Unlocking the potential of antibody-drug conjugates for cancer therapy","volume":"18","author":"Drago","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104787_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2022.101795","article-title":"Treatment-related adverse events associated with HER2-Targeted antibody-drug conjugates in clinical trials: a systematic review and meta-analysis","volume":"55","author":"Fu","year":"2023","journal-title":"eClinicalMedicine"},{"key":"10.1016\/j.critrevonc.2025.104787_bib18","doi-asserted-by":"crossref","first-page":"4852","DOI":"10.1200\/JCO.23.01361","article-title":"Trastuzumab deruxtecan in patients with HER2-mutant metastatic non-small-cell lung cancer: primary results from the randomized, phase II DESTINY-lung02 trial","volume":"41","author":"Goto","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104787_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.103715","article-title":"Detection of antibody-drug conjugate-induced interstitial lung disease using circulating cell-free DNA","volume":"9","author":"Grinshpun","year":"2024","journal-title":"ESMO Open"},{"key":"10.1016\/j.critrevonc.2025.104787_bib20","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1111\/jcpt.13777","article-title":"Safety of trastuzumab deruxtecan: a meta-analysis and pharmacovigilance study","volume":"47","author":"Guo","year":"2022","journal-title":"J. Clin. Pharm. Ther."},{"key":"10.1016\/j.critrevonc.2025.104787_bib21","doi-asserted-by":"crossref","first-page":"3717","DOI":"10.1038\/s41591-024-03261-7","article-title":"Trastuzumab deruxtecan in HER2-positive advanced breast cancer with or without brain metastases: a phase 3b\/4 trial","volume":"30","author":"Harbeck","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.critrevonc.2025.104787_bib22","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The cochrane collaboration\u2019s tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"10.1016\/j.critrevonc.2025.104787_bib23","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S0140-6736(22)02420-5","article-title":"Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial","volume":"401","author":"Hurvitz","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.critrevonc.2025.104787_bib24","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1007\/s40264-020-00968-7","article-title":"Interstitial lung disease as an adverse drug reaction in japan: exploration of regulatory actions as a basis for high reporting","volume":"43","author":"Iwasa","year":"2020","journal-title":"Drug Saf."},{"key":"10.1016\/j.critrevonc.2025.104787_bib25","doi-asserted-by":"crossref","first-page":"S878","DOI":"10.1016\/j.annonc.2024.08.1467","article-title":"1401O Trastuzumab deruxtecan (T-DXd) monotherapy and combinations in patients (pts) with advanced\/metastatic HER2-positive (HER2+) esophageal, gastric or gastroesophageal junction adenocarcinoma (GEJA): DESTINY-Gastric03 (DG-03)","volume":"35","author":"Janjigian","year":"2024","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104787_bib26","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.16_suppl.8543","article-title":"Trastuzumab deruxtecan (T-DXd) in patients with HER2-mutant metastatic non- small cell lung cancer (mNSCLC): final analysis results of DESTINY-Lung02","volume":"42","author":"Janne","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104787_bib27","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.SABCS23-RF02-03","article-title":"Trastuzumab deruxtecan (T-DXd) in combination with anastrozole or fulvestrant in patients with HER2-low HR+\u2009advanced\/metastatic breast cancer: a Phase 1b, open-label, multicenter, dose-expansion study (DESTINY-Breast08)","volume":"84","author":"Jhaveri","year":"2024","journal-title":"Cancer Res."},{"key":"10.1016\/j.critrevonc.2025.104787_bib28","doi-asserted-by":"crossref","first-page":"2608","DOI":"10.1038\/s41467-024-46945-x","article-title":"Outcome differences by sex in oncology clinical trials","volume":"15","author":"Kammula","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.critrevonc.2025.104787_bib29","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1093\/annonc\/mdx286","article-title":"Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review","volume":"28","author":"Khoja","year":"2017","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104787_bib30","doi-asserted-by":"crossref","first-page":"S613","DOI":"10.1016\/j.annonc.2024.08.909","article-title":"849O Phase II study of trastuzumab deruxtecan in patients with HER2-positive recurrent\/metastatic salivary gland cancer: Results from the MYTHOS trial","volume":"35","author":"Kinoshita","year":"2024","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104787_bib31","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1093\/jjco\/hyad036","article-title":"The efficacy and safety of trastuzumab deruxtecan (T-DXd) in HER2-expressing solid tumours: a single-arm meta-analysis","volume":"53","author":"Kou","year":"2023","journal-title":"Jpn J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104787_bib32","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.16_suppl.1006","article-title":"An age-specific pooled analysis of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-positive (HER2+) metastatic breast cancer (mBC) from DESTINY-Breast01, -02, and -03","author":"Krop","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104787_bib33","article-title":"Efficacy and safety of trastuzumab deruxtecan in the treatment of HER2-low\/positive advanced breast cancer: a single-arm meta-analysis","volume":"14","author":"Li","year":"2023","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.critrevonc.2025.104787_bib34","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/S1470-2045(24)00140-2","article-title":"Trastuzumab deruxtecan in patients with solid tumours harbouring specific activating HER2 mutations (DESTINY-PanTumor01): an international, phase 2 study","volume":"25","author":"Li","year":"2024","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2025.104787_bib35","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1056\/NEJMoa2112431","article-title":"Trastuzumab deruxtecan in HER2-mutant non\u2013small-cell lung cancer","volume":"386","author":"Li","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2025.104787_bib36","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1000100","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration","volume":"6","author":"Liberati","year":"2009","journal-title":"PLOS Med."},{"key":"10.1016\/j.critrevonc.2025.104787_bib37","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1111\/cts.12771","article-title":"Pharmacogenomics in Asian subpopulations and impacts on commonly prescribed medications","volume":"13","author":"Lo","year":"2020","journal-title":"Clin. Transl. Sci."},{"key":"10.1016\/j.critrevonc.2025.104787_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2024.104305","article-title":"Efficacy and safety of trastuzumab deruxtecan in treating human epidermal growth factor receptor 2-low\/positive advanced breast cancer:a meta-analysis of randomized controlled trials","volume":"196","author":"Ma","year":"2024","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.critrevonc.2025.104787_bib39","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1080\/17512433.2022.2121705","article-title":"Interstitial lung disease associated with anti-HER2 anti-body drug conjugates: results from clinical trials and the WHO\u2019s pharmacovigilance database","volume":"15","author":"Ma","year":"2022","journal-title":"Expert Rev. Clin. Pharmacol."},{"key":"10.1016\/j.critrevonc.2025.104787_bib40","article-title":"Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors: primary results from the DESTINY-pantumor02 phase II trial","volume":"42","author":"Meric-Bernstam","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104787_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.102233","article-title":"Trastuzumab deruxtecan in human epidermal growth factor receptor 2-positive breast cancer brain metastases: a systematic review and meta-analysis","volume":"9","author":"Michelon","year":"2024","journal-title":"ESMO Open"},{"key":"10.1016\/j.critrevonc.2025.104787_bib42","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2203690","article-title":"Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer","volume":"387","author":"Modi","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2025.104787_bib43","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1200\/JCO.19.02318","article-title":"Antitumor activity and safety of trastuzumab deruxtecan in patients with HER2-low-expressing advanced breast cancer: results from a phase Ib study","volume":"38","author":"Modi","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104787_bib44","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1056\/NEJMoa1914510","article-title":"Trastuzumab deruxtecan in previously treated HER2-positive breast cancer","volume":"382","author":"Modi","year":"2020","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.critrevonc.2025.104787_bib45","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1038\/s41591-023-02478-2","article-title":"Trastuzumab deruxtecan in metastatic breast cancer with variable HER2 expression: the phase 2 DAISY trial","volume":"29","author":"Mosele","year":"2023","journal-title":"Nat. Med."},{"key":"10.1016\/j.critrevonc.2025.104787_bib46","doi-asserted-by":"crossref","first-page":"3012","DOI":"10.1200\/JCO.2011.40.3824","article-title":"The price we pay for progress: a meta-analysis of harms of newly approved anticancer drugs","volume":"30","author":"Niraula","year":"2012","journal-title":"JCO"},{"key":"10.1016\/j.critrevonc.2025.104787_bib47","doi-asserted-by":"crossref","first-page":"2789","DOI":"10.1200\/JCO.22.02558","article-title":"Trastuzumab deruxtecan for human epidermal growth factor receptor 2-expressing advanced or recurrent uterine carcinosarcoma (NCCH1615): the STATICE trial","volume":"41","author":"Nishikawa","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104787_bib48","doi-asserted-by":"crossref","first-page":"4806","DOI":"10.1158\/1078-0432.CCR-09-0344","article-title":"Cancer pharmacoethnicity: ethnic differences in susceptibility to the effects of chemotherapy","volume":"15","author":"O\u2019Donnell","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2025.104787_bib49","doi-asserted-by":"crossref","first-page":"5097","DOI":"10.1158\/1078-0432.CCR-15-2822","article-title":"DS-8201a, a novel HER2-targeting ADC with a novel DNA topoisomerase I inhibitor, demonstrates a promising antitumor efficacy with differentiation from T-DM1","volume":"22","author":"Ogitani","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2025.104787_bib50","doi-asserted-by":"crossref","first-page":"3207","DOI":"10.1200\/JCO.23.02010","article-title":"Trastuzumab deruxtecan in human epidermal growth factor receptor 2-expressing biliary tract cancer (HERB; NCCH1805): a multicenter, single-arm, phase II trial","volume":"42","author":"Ohba","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104787_bib51","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1093\/neuonc\/noac144","article-title":"Trastuzumab deruxtecan in patients with central nervous system involvement from HER2-positive breast cancer: The DEBBRAH trial","volume":"25","author":"P\u00e9rez-Garc\u00eda","year":"2023","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.critrevonc.2025.104787_bib52","doi-asserted-by":"crossref","first-page":"S46","DOI":"10.1016\/j.jtho.2024.09.082","article-title":"OA16.05 trastuzumab deruxtecan monotherapy in pretreated HER2-overexpressing nonsquamous non-small cell lung cancer: DESTINY-lung03 Part 1","volume":"19","author":"Planchard","year":"2024","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104787_bib53","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2021-CT167","article-title":"Pooled analysis of drug-related interstitial lung disease (ILD) in 8 single-arm trastuzumab deruxtecan (T-DXd) studies","volume":"81","author":"Powell","year":"2021","journal-title":"Cancer Res."},{"key":"10.1016\/j.critrevonc.2025.104787_bib54","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S1470-2045(24)00380-2","article-title":"Trastuzumab deruxtecan in patients with HER2-positive advanced colorectal cancer (DESTINY-CRC02): primary results from a multicentre, randomised, phase 2 trial","volume":"25","author":"Raghav","year":"2024","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2025.104787_bib55","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.16_suppl.11527","article-title":"PEPN1924, a phase 2 study of trastuzumab deruxtecan (DS-8201a, T-DXd) in adolescents and young adults with recurrent HER2+\u2009osteosarcoma: A children\u2019s oncology group pediatric early-phase clinical trial network study","volume":"41","author":"Reed","year":"2023","journal-title":"JCO"},{"key":"10.1016\/j.critrevonc.2025.104787_bib56","unstructured":"Research, C. for D.E. and, 2024. FDA grants accelerated approval to fam-trastuzumab deruxtecan-nxki for unresectable or metastatic HER2-positive solid tumors. FDA."},{"key":"10.1016\/j.critrevonc.2025.104787_bib57","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100553","article-title":"Optimizing treatment management of trastuzumab deruxtecan in clinical practice of breast cancer","volume":"7","author":"Rugo","year":"2022","journal-title":"ESMO Open"},{"key":"10.1016\/j.critrevonc.2025.104787_bib58","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1200\/OP.22.00480","article-title":"Real-world perspectives and practices for pneumonitis\/interstitial lung disease associated with trastuzumab deruxtecan use in human epidermal growth factor receptor 2\u2013expressing metastatic breast cancer","volume":"19","author":"Rugo","year":"2023","journal-title":"JCO Oncol. Pract."},{"issue":"24","key":"10.1016\/j.critrevonc.2025.104787_bib59","first-page":"S0923","volume":"36","author":"Sakai","year":"2024","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104787_bib60","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2024.102865","article-title":"Efficacy and safety of antibody-drug conjugates in pretreated HER2-low metastatic breast cancer: a systematic review and network meta-analysis","volume":"132","author":"Schettini","year":"2025","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.critrevonc.2025.104787_bib61","doi-asserted-by":"crossref","first-page":"S1542","DOI":"10.1016\/j.annonc.2023.10.307","volume":"34","author":"Shen","year":"2023","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104787_bib62","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1002\/cpt.2757","article-title":"Effect of trastuzumab deruxtecan on QT\/QTc interval and pharmacokinetics in HER2-positive or HER2-low metastatic\/unresectable breast cancer","volume":"113","author":"Shimomura","year":"2023","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.critrevonc.2025.104787_bib63","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1056\/NEJMoa2004413","article-title":"Trastuzumab deruxtecan in previously treated HER2-positive gastric cancer","volume":"382","author":"Shitara","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2025.104787_bib64","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/S1470-2045(19)30088-9","article-title":"Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive gastric cancer: a dose-expansion, phase 1 study","volume":"20","author":"Shitara","year":"2019","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2025.104787_bib65","doi-asserted-by":"crossref","first-page":"S994","DOI":"10.1016\/j.annonc.2022.07.1103","article-title":"975P Trastuzumab deruxtecan in patients (pts) with HER2-overexpressing (HER2-OE) metastatic non-small cell lung cancer (NSCLC): Results from the DESTINY-Lung01 trial","volume":"33","author":"Smit","year":"2022","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104787_bib66","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/S1470-2045(24)00064-0","article-title":"Trastuzumab deruxtecan in patients with metastatic non-small-cell lung cancer (DESTINY-Lung01): primary results of the HER2-overexpressing cohorts from a single-arm, phase 2 trial","volume":"25","author":"Smit","year":"2024","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2025.104787_bib67","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2023.101613","article-title":"Incidence of interstitial lung disease and cardiotoxicity with trastuzumab deruxtecan in breast cancer patients: a systematic review and single-arm meta-analysis","volume":"8","author":"Soares","year":"2023","journal-title":"ESMO Open"},{"key":"10.1016\/j.critrevonc.2025.104787_bib68","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1002\/jrsm.1211","article-title":"Neither fixed nor random: weighted least squares meta-regression","volume":"8","author":"Stanley","year":"2017","journal-title":"Res. Synth. Methods"},{"key":"10.1016\/j.critrevonc.2025.104787_bib69","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2022.102378","article-title":"Multidisciplinary clinical guidance on trastuzumab deruxtecan (T-DXd)-related interstitial lung disease\/pneumonitis-Focus on proactive monitoring, diagnosis, and management","volume":"106","author":"Swain","year":"2022","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.critrevonc.2025.104787_bib70","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1002\/sim.1761","article-title":"What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data","volume":"23","author":"Sweeting","year":"2004","journal-title":"Stat. Med."},{"key":"10.1016\/j.critrevonc.2025.104787_bib71","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.3_suppl.309","article-title":"Phase 2 study of trastuzumab deruxtecan as neoadjuvant treatment for HER2-positive gastric and gastroesophageal junction adenocarcinoma (EPOC2003)","volume":"42","author":"Takahari","year":"2024","journal-title":"JCO"},{"key":"10.1016\/j.critrevonc.2025.104787_bib72","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/S1470-2045(19)30097-X","article-title":"Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study","volume":"20","author":"Tamura","year":"2019","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2025.104787_bib73","doi-asserted-by":"crossref","DOI":"10.1200\/OP.23.00097","article-title":"Detecting and managing T-DXd-related interstitial lung disease: the five \u201cS\u201d rules","volume":"19","author":"Tarantino","year":"2023","journal-title":"JCO Oncol. Pract."},{"key":"10.1016\/j.critrevonc.2025.104787_bib74","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1158\/2159-8290.CD-19-1014","article-title":"Targeting HER2 with trastuzumab deruxtecan: a dose-expansion, phase i study in multiple advanced solid tumors","volume":"10","author":"Tsurutani","year":"2020","journal-title":"Cancer Discov."},{"key":"10.1016\/j.critrevonc.2025.104787_bib75","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1200\/JCO.21.02377","article-title":"Sex differences in risk of severe adverse events in patients receiving immunotherapy, targeted therapy, or chemotherapy in cancer clinical trials","volume":"40","author":"Unger","year":"2022","journal-title":"JCO"},{"key":"10.1016\/j.critrevonc.2025.104787_bib76","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1007\/s00228-022-03332-z","article-title":"Sex differences in serious adverse drug reactions in patients receiving immunotherapy, targeted therapy, or chemotherapy: a disproportionality analysis of the VigiBase\u00ae","volume":"78","author":"Wabont","year":"2022","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.critrevonc.2025.104787_bib77","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1186\/s12885-022-10015-6","article-title":"Safety and efficacy profile of Trastuzumab deruxtecan in solid cancer: pooled reanalysis based on clinical trials","volume":"22","author":"Xu","year":"2022","journal-title":"BMC Cancer"},{"key":"10.1016\/j.critrevonc.2025.104787_bib78","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.23.02626","article-title":"Trastuzumab deruxtecan in advanced solid tumors with human epidermal growth factor receptor 2 amplification identified by plasma cell-free DNA testing: a multicenter, single-arm, phase II basket trial","volume":"42","author":"Yagisawa","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104787_bib79","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1200\/JCO.22.00575","article-title":"Trastuzumab deruxtecan in anti-human epidermal growth factor receptor 2 treatment-naive patients with human epidermal growth factor receptor 2-low gastric or gastroesophageal junction adenocarcinoma: exploratory cohort results in a phase II trial","volume":"41","author":"Yamaguchi","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104787_bib80","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1002\/cpt.2291","article-title":"Exposure-response relationships in patients with HER2-positive metastatic breast cancer and other solid tumors treated with trastuzumab deruxtecan","volume":"110","author":"Yin","year":"2021","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.critrevonc.2025.104787_bib81","doi-asserted-by":"crossref","first-page":"3332","DOI":"10.1038\/s41467-023-38032-4","article-title":"Final results of DESTINY-CRC01 investigating trastuzumab deruxtecan in patients with HER2-expressing metastatic colorectal cancer","volume":"14","author":"Yoshino","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.critrevonc.2025.104787_bib82","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.annonc.2019.11.019","article-title":"The art of innovation: clinical development of trastuzumab deruxtecan and redefining how antibody-drug conjugates target HER2-positive cancers","volume":"31","author":"Yver","year":"2020","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104787_bib83","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1002\/cncr.34507","article-title":"Treatment-related adverse events of antibody-drug conjugates in clinical trials: a systematic review and meta-analysis","volume":"129","author":"Zhu","year":"2023","journal-title":"Cancer"}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842825001751?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842825001751?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,25]],"date-time":"2025-08-25T20:45:01Z","timestamp":1756154701000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842825001751"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":83,"alternative-id":["S1040842825001751"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2025.104787","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Adverse effect of trastuzumab deruxtecan in solid tumours: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2025.104787","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104787"}}